ArticleOncotarget2017
Th1high in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Distinct T helper cell-mediated antitumor immunity: T helper 2 cells in focus.Cancer pathogenesis and therapy · 2023Review
- Mechanisms of immune regulation for acupuncture on chronic respiratory diseases.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Article
- [Research Status of Tumor-associated Fibroblasts Regulating Immune Cells].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- Article
- Stimulation of Innate and Adaptive Immune Cells with Graphene Oxide and Reduced Graphene Oxide Affect Cancer Progression.Archivum immunologiae et therapiae experimentalis · 2021Review
- APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC.BMC cancer · 2021Article
- Chemotherapy-induced changes in bronchoalveolar lavage fluid CD4 + and CD8 + cells of the opposite lung to the cancer.Scientific reports · 2020Article
- Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity.Pharmaceutics · 2020Review
- The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.Nature reviews. Cancer · 2020Review
- A Novel Nomogram Based on Immune Scores for Predicting Survival in Patients with Early-Stage Non-Small Cell Lung Cancer (NSCLC).Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods.Cancer medicine · 2020Article
- Analysis of Expression and Its Clinical Significance of the Secreted Phosphoprotein 1 in Lung Adenocarcinoma.Frontiers in genetics · 2020Article
- [Research Progress of Treg/Th17 in the Treatment of Chronic Obstructive Pulmonary Disease with Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
- A high-risk luminal A dominant breast cancer subtype with increased mobility.Breast cancer research and treatment · 2019Article
- Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer.Pharmacology & therapeutics · 2019Review
- Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode.Cancer biology & medicine · 2017Article
- Effect of Peripheral Blood Lymphocytes on Prognosis of Multiple Cancers.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD4+Th subsets play an important role in tumor progression but their expression characteristics and clinical significance in human tumor microenvironment remains unclear. In this study, we aim to analyze the expression and clinical significance of tissue-infiltrating Th1, Th2 and Th17 in lung cancer by flow cytometry. We found that the frequency of CD3+CD4+IFN-γ+Th1 in tumor nest was significantly lower than that in tumor boundary, adjacent normal lung tissue or corresponding lymph node tissue; the frequency of CD3+CD4+IL-4+Th2 in tumor nest was significantly higher than that in tumor boundary, adjacent normal lung tissue or corresponding lymph node tissue; the frequency of CD3+CD4+IL-17+Th17 in tumor nest was significantly lower than that in tumor boundary, but not adjacent normal tissue or corresponding lymph node tissue. Survival analysis of 2-years survival after surgery showed that Th1high group was significantly lower compared with Th1low group; Th2high and Th17low is a good prognosis index compared with the Th2low and Th17high groups respectively, but this difference failed to significance. In addition, we also found that PD-1 expression showed a high level on lung tumor tissues and adjacent non- tumor tissue infiltrating T cells, and no significant difference was found between the two groups. However PD-L1 on CD45+CD14+mononcytes/macrophages in tumor tissue show a significantly higher level compared with that in adjacent nontumor tissues. In vitro stimulation experiments showed that IFN-γ could significantly increase PD-L1 expression on monocyte. In conclusion, we for the first time found Th1high is a poor indicator for prognosis of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.